We are live on ! Find out more
CTXR icon

Citius Pharmaceuticals
CTXR

22 hedge funds and large institutions have $1.85M invested in Citius Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 5

70% more capital invested

Capital invested by funds: $1.09M → $1.85M (+$759K)

38% more funds holding

Funds holding: 16 → 22 (+6)

0.05% more ownership

Funds ownership: 0.08% → 0.13% (+0.05%)

Holders
22
Holders Change
+6
Holders Change %
+37.5%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
6
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$190K
2
HighTower Advisors
HighTower Advisors
Illinois
+$177K
3
WAS
Wealth Advisory Solutions
Indiana
+$110K
4
UBS Group
UBS Group
Switzerland
+$107K
5
Osaic Holdings
Osaic Holdings
Arizona
+$49.5K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$92K
2
TRCT
Tower Research Capital (TRC)
New York
-$9K
3
GT
Glenmede Trust
Pennsylvania
-$2K
4
FFA
Founders Financial Alliance
North Carolina
-$1K
5
FCA
FinTrust Capital Advisors
South Carolina
-$2
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$770K +$190K +7,287 +32%
HighTower Advisors
2
HighTower Advisors
Illinois
$174K +$177K +6,798 New
VF
3
Virtu Financial
New York
$151K +$34.9K +1,338 +29%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$147K – – –
WAS
5
Wealth Advisory Solutions
Indiana
$107K +$110K +4,234 New
UBS Group
6
UBS Group
Switzerland
$104K +$107K +4,087 New
Northern Trust
7
Northern Trust
Illinois
$79K +$36.7K +1,406 +84%
Osaic Holdings
8
Osaic Holdings
Arizona
$54K +$49.5K +1,900 +950%
MIM
9
Miller Investment Management
Pennsylvania
$51K +$26.1K +1,000 +100%
GCP
10
GSA Capital Partners
United Kingdom
$35K +$35.3K +1,353 New
FIG
11
Freed Investment Group
Massachusetts
$29K +$29.7K +1,140 New
Renaissance Technologies
12
Renaissance Technologies
New York
$22K +$22.2K +851 New
TSS
13
Two Sigma Securities
New York
$21K +$21.4K +822 New
WSTAM
14
Wilbanks Smith & Thomas Asset Management
Virginia
$20K – – –
WAM
15
Warberg Asset Management
Illinois
$20K +$20.9K +800 New
Citadel Advisors
16
Citadel Advisors
Florida
$19K +$19.7K +756 New
T. Rowe Price Associates
17
T. Rowe Price Associates
Maryland
$11K +$10.8K +416 New
CHA
18
Cooper/Haims Advisors
New York
$10K – – –
US Bancorp
19
US Bancorp
Minnesota
$10K – – –
Millennium Management
20
Millennium Management
New York
$10K +$10.5K +402 New
CP
21
Corbenic Partners
Pennsylvania
$2K – – –
Wells Fargo
22
Wells Fargo
California
$2K +$26 +1 +1%
SM
23
Sabby Management
Florida
– -$92K -3,548 Closed
TRCT
24
Tower Research Capital (TRC)
New York
– -$9K -337 Closed
GT
25
Glenmede Trust
Pennsylvania
– -$2K -80 Closed
1
2

CTXR Hedge Fund Activity: Q4 2020 in Review

22 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q4 2020, worth a combined $1.85M — up 70% from $1.09M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new CTXR positions and 5 closed out — a net gain of 6 holders — while 6 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, adding an estimated $190K. The largest seller was Sabby Management, exiting entirely with an estimated $92K sold.

  • 22 institutional investors held Citius Pharmaceuticals (CTXR) as of Q4 2020, up from 16 in Q3 2020.
  • Funds reported $1.85M of Citius Pharmaceuticals stock for Q4 2020, up 70% quarter-over-quarter.
  • 11 funds opened new Citius Pharmaceuticals positions in Q4 2020 and 5 closed out, a net change of +6 holders.
  • The largest Citius Pharmaceuticals buyer in Q4 2020 was Vanguard Group, an estimated $190K added.
  • The largest Citius Pharmaceuticals seller in Q4 2020 was Sabby Management, an estimated $92K sold.

Based on aggregated 13F filings for Q4 2020.